United States Patent 9,662,312: Scope, Claim Construction, and US Patent Landscape for Glomerulosclerosis Treatment
Executive summary: US Patent 9,662,312 is a method-of-treatment patent for glomerulosclerosis using a compound of “Formula I” (and pharmaceutically acceptable salts). The independent claim is limited by route-agnostic dosing amounts of 200 mg/day, 400 mg/day, or 800 mg/day. The dependent claims narrow dosing to a single daily dose within that set. The practical enforcement scope is therefore driven less by administration timing or patient selection (not stated in your excerpts) and more by whether accused dosing uses one of the claimed daily dose amounts with the claimed Formula I compound (or a salt).
Because the patent is defined around Formula I, the key determinants of infringement and validity are: (i) the exact identity and structural definition of Formula I, (ii) whether a competitor product uses that same chemical entity (or an equivalent salt that qualifies as “pharmaceutically acceptable”), and (iii) whether the competitor’s regimen falls within 200/400/800 mg/day.
What does US Patent 9,662,312 claim for glomerulosclerosis?
Core claim concept (Claim 1):
A “method of treating glomerulosclerosis” by administering an effective amount of a Formula I compound (or pharmaceutically acceptable salt) to a subject in need, where the administered amount is 200 mg/day, 400 mg/day, or 800 mg/day.
Claim 1 structure (infringement-relevant elements):
- Medical indication: “treating glomerulosclerosis”
- Treatment target: “a subject in need thereof”
- Active ingredient: a compound of Formula I (or pharmaceutically acceptable salt)
- Exposure constraint: daily dose must be exactly one of the three values:
- 200 mg/day
- 400 mg/day
- 800 mg/day
- No explicit route, schedule, or regimen structure is provided in the claim excerpt you gave.
Dependent claims (Claims 2–4):
- Claim 2: dose is 200 mg/day
- Claim 3: dose is 400 mg/day
- Claim 4: dose is 800 mg/day
These dependent claims are straightforward dose-partitioning. They matter for claim construction because they reduce ambiguity: if an accused regimen can be mapped to a specific daily dose, the corresponding dependent claim is a direct fit.
How broad is the “Formula I” limitation in US 9,662,312?
Direct answer: The breadth of US 9,662,312 is dominated by how Formula I is defined in the specification. Your excerpts do not include the chemical structure or substituent definitions, so the enforceable scope cannot be fully mapped to specific marketed molecules or specific salt forms without the Formula I definition.
Claim scope implications that follow from the claim language:
- The claim is chemical-structure constrained. A competitor avoids infringement if their compound is outside Formula I, even if it achieves glomerulosclerosis treatment.
- The claim includes pharmaceutically acceptable salts. Competitors can face infringement risk not only from the free base/acid but also from salt selection, depending on whether their salt qualifies as “pharmaceutically acceptable” and structurally matches the Formula I entity.
- The claim language uses “a compound of Formula I” (singular/alternative). This supports a reading that any member of the Formula I genus that satisfies the definition is covered, but only members that truly fall inside Formula I are covered.
Practical enforcement takeaways:
- Portfolio mapping and freedom-to-operate analysis will hinge on whether the competitor compound is literally within Formula I or can be designed around by changing the core scaffold or key substituents.
- Salt form strategy is not a complete escape if the salt corresponds to the same Formula I compound.
Is the daily dose requirement a strict limitation or an “effective amount” wrapper in claim 1?
Short answer: Claim 1 contains both “effective amount” and a specific daily dose set. In patent claim practice, this is typically treated as a combined limitation: the accused method must use the claimed compound and administer it at 200/400/800 mg/day.
Why the 200/400/800 mg/day language is likely central to construction:
- The claim states: “wherein the amount … administered … is 200 mg/day, 400 mg/day, or 800 mg/day.”
- That phrase reads as a measurable administered amount limitation, not merely a preference.
Infringement mapping consequences for enforcement and design-around:
- A regimen at a non-listed dose (example: 300 mg/day) would not satisfy that numeric limitation if construed literally.
- A regimen that varies day-to-day could be litigated on what constitutes “the amount … administered” for the method. If the method uses mixed dosing (for example, titration), the plaintiff’s strategy would often be to identify a step of administration that matches one of the listed daily doses, while defense would argue the method does not meet the claimed dose limitation as a whole. The claim text you provided does not clarify single-dose vs multi-step titration.
What range of dosing is covered: exact 200/400/800 mg/day or a broader dosage window?
Answer based on claim text you provided: The claim text uses discrete daily dose values. It does not state a range such as “about 200 mg/day” or “200-800 mg/day.”
Scope consequence:
- Covered dosing is limited to 200 mg/day, 400 mg/day, and 800 mg/day as claimed.
- Absent “about” or tolerance language, the patent’s asserted scope is typically argued as exact. That tends to make it easier for a design-around to pick an adjacent dose and attempt to avoid the claim.
Risk points for competitors:
- If clinical protocols include dosing that matches one of the claimed daily amounts, the method claim risk increases.
- If compendial or labeling information includes those exact daily doses for the Formula I compound in glomerulosclerosis, that can be used to support inducement or direct method practice theories, depending on who performs the steps.
What does claim 1 cover in terms of regimen details (timing, route, frequency)?
Answer: Based on the claim excerpt, the method is route-agnostic and schedule-agnostic because it only specifies daily dose amount.
What the claim excerpt does not limit (based on your text):
- No route (oral vs IV vs subcutaneous) is stated.
- No frequency (once daily vs split dosing) is stated.
- No titration or duration is stated.
- No patient subgroup is stated (age, CKD stage, proteinuria level, etiology).
How that affects scope:
- If the same daily dose is delivered via any route, the compound and dose limitations could still be satisfied.
- If a competitor uses a different route but the same mg/day and same Formula I compound, infringement risk remains.
What types of competitor products could infringe: formulations, salts, and dosing regimens
Formulation patents vs method-of-treatment patents
US 9,662,312 is a method-of-use claim. It does not, from your excerpt, claim a composition or formulation. That changes the competitive analysis:
- A competitor with a different formulation is not automatically safe if their product is used to administer the Formula I compound at one of the claimed daily doses for glomerulosclerosis.
- Conversely, a competitor can have a formulation that avoids any composition-level claims, while still risking infringement of a method claim if dosing and indication align.
Salt forms
Because the claim includes “pharmaceutically acceptable salt,” salt selection is not a guaranteed carve-out. In practice, infringement analysis often focuses on whether the accused active is the same chemical entity encompassed by Formula I, with an included acceptable salt.
Dose regimens
The numeric limitation makes the dosing schedule a key litigation focal point. A competitor’s product label and clinical trial dosing arms are the first places plaintiffs look to establish mapping to 200/400/800 mg/day.
What patents typically surround this kind of method-of-treatment claim in the US?
Answer: The landscape around a method claim like this generally clusters into four groups:
- Compound (composition or structural) patents that define and claim the chemical scaffold in Formula I (often as compositions, salts, or specific embodiments).
- Method-of-treatment patents that claim indication and patient use, often including dose levels or clinical endpoints.
- Formulation and dosing device patents (if the active is used as a drug product with particular release profiles).
- Regimen/dosing patents that may claim different daily dose amounts, titration steps, duration, or combination therapy.
Given your excerpt only includes method claims limited to dosing amounts, the likely “layering” is:
- Chemical coverage for Formula I members upstream (broader, structural claims).
- Dose-limited method coverage downstream (narrower, numeric constraints like 200/400/800 mg/day).
This layering can create a situation where a competitor can design around one dose value but still faces coverage under other dose-related claims or combination therapy claims.
When does US 9,662,312 expire, and how does exclusivity interact?
Executive summary: Your excerpt does not provide filing date, priority date, patent term adjustment (PTA), patent term extension (PTE), maintenance status, or whether it is tied to a specific FDA-identified reference product. Without those inputs, a precise expiration date cannot be calculated.
What can be said from claim form alone:
- US method patents have the same baseline 20-year term from earliest effective filing date, subject to PTA/PTE. Expiration timing affects whether generics or biosimilar-style approaches are viable.
What is the Orange Book status and generic-entry risk for a method-of-use patent like 9,662,312?
Executive summary: Your excerpt does not include the active ingredient name, NDC, NDA/BLA, or Orange Book listings. A specific Orange Book status determination is not possible from claim text alone.
Method-of-use risk mechanics that follow from the claim:
- Orange Book listing is typically required for method-of-use patents tied to FDA-approved drug products.
- If listed and tied to an approved labeling dose that matches 200/400/800 mg/day for glomerulosclerosis, an ANDA filer can face infringement allegations under paragraph IV (assuming the product is the same Formula I drug and used per labeling).
Dosing specificity effect:
- Narrow numeric dosing can reduce the set of label instructions that match the patent, which can narrow the paragraph IV risk in some scenarios.
- If the FDA-approved labeling uses those same daily doses, risk increases.
How strong is the patent estate based on the claims provided?
Answer: Based strictly on your excerpt, the claim set is narrower than typical scaffold-only coverage because it is limited to:
- a specific compound definition (Formula I),
- and specific daily dose numbers.
At the same time, the claim set can be enforceable where competitors can be shown to use the same compound at one of the listed daily dose values to treat glomerulosclerosis.
Strength drivers that are not visible in your excerpt:
- Whether “Formula I” is broad or narrow in the specification.
- Whether the specification provides robust definitions and support for each member of Formula I.
- Whether there are additional claims in the patent covering other dosing schedules, ranges, or combination regimens.
Patent claim comparison: how claims 2–4 change enforcement strategy
Claim 1 (200/400/800 mg/day):
Enforcement under Claim 1 potentially covers all three daily doses. Plaintiff can choose the easiest-to-prove dosing arm.
Claim 2 (200 mg/day), Claim 3 (400 mg/day), Claim 4 (800 mg/day):
These create discrete enforcement targets:
- If a competitor’s regimen uses only one dose value, the corresponding dependent claim is the cleanest fit.
- A design-around that uses non-listed doses is better targeted against the dependent claims, which are narrower.
Key takeaways
- US 9,662,312 is a method-of-treating glomerulosclerosis patent that hinges on two core limitations: use of a compound of Formula I (or pharmaceutically acceptable salts) and dosing at exact daily amounts of 200, 400, or 800 mg/day.
- The daily dose numbers are likely treated as true claim limitations, not merely “effective amount” guidance, given the explicit “is 200/400/800 mg/day” wording.
- Claims 2–4 narrow the independent claim by locking dosing to a single value, which sharpens both infringement mapping and design-around planning.
- The overall commercial and litigation landscape around this patent will depend on (i) what exact chemical structure Formula I covers and (ii) what dosing values appear in FDA labeling, clinical protocols, and product use instructions for the Formula I compound in glomerulosclerosis.
FAQs
1) How do I determine whether a competitor dose “matches” 200/400/800 mg/day?
Focus on the total daily mg of active compound administered over a 24-hour period as described by labeling and/or actual clinical protocols. The claim text uses discrete daily values, so near-miss regimens must be evaluated for literal correspondence to the claimed daily dose.
2) Does US 9,662,312 require a specific route of administration?
No route is stated in the claim excerpt. Scope turns on whether the daily dose and compound definition match, irrespective of route.
3) Do salt forms change infringement risk under the patent?
The claim includes “pharmaceutically acceptable salts,” so switching to a different salt does not necessarily avoid infringement if the active salt corresponds to the Formula I compound and qualifies as pharmaceutically acceptable.
4) Can a competitor avoid infringement by titrating across dose levels?
A titration regimen can create evidentiary fights over whether the method “administers” one of the claimed daily amounts as part of the claimed treatment method. The claim excerpt does not specify titration exclusions.
5) What is the most likely enforcement evidence for a method-of-use patent with dose-specific claims?
FDA-approved labeling instructions, clinical trial dosing arms, and real-world dosing data that show administration of the Formula I compound at 200/400/800 mg/day for glomerulosclerosis.
References
- United States Patent and Trademark Office. US Patent No. 9,662,312.
